-- Features proprietary OXINIUM(TM) DH material; eliminates Cobalt Chrome 
alloy reducing wear and corrosion risks [1]

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today 
announces the launch of its OR3O Dual Mobility System for use in primary and 
revision hip arthroplasty in Japan. Compared with traditional solutions, dual 
mobility implants have a small diameter femoral head that locks into a larger 
polyethylene insert - increasing stability, reducing dislocation risk, and 
offering improved range of motion.[2]

Photo - https://mma.prnewswire.com/media/1901757/Smith_Nephew_OR3O.jpg
Logo - https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg

While most competitive devices utilize a Cobalt Chrome (CoCr) liner along with 
CoCr or ceramic head balls, OR3O incorporates Smith+Nephew’s latest advanced 
bearing surface, OXINIUM DH, for its liner and proprietary OXINIUM on XLPE for 
its femoral head and polyethylene inserts. This eliminates both the modular 
CoCr liner and/or CoCr head ball from the construct - reducing wear and 
corrosion risks that have been associated with the alloy. [1]

OXINIUM DH (Diffusion Hardened) is a unique variation of Smith+Nephew’s OXINIUM 
Technology platform that increases the depth of hardening through an additive 
manufacturing process. 

The modular dual mobility segment was introduced to Japan in 2013 and has 
continued to grow globally. Post-operative dislocation is the second most 
common reason for revision of a total hip replacement globally [3-6] and 
remains a serious concern for surgeons when performing total hip arthroplasty. 
Studies have shown dual mobility is uniquely positioned to manage dislocation, 
better than metal-on-metal or ceramic-on-ceramic large head series. [7]

“Smith+Nephew’s OR3O Dual Mobility System is a groundbreaking introduction for 
Japan that offers technology not available in competitive systems,” said Shinya 
Dobashi, Senior Vice President and Managing Director, North Asia, Smith+Nephew. 
“Over a dozen peer reviewed publications have now cited or expressed concerns 
over corrosion or elevated ions in CoCr modular dual mobility liners.[8-20] The 
reduced corrosion [1] of our OXINIUM and OXINIUM DH bearing surface sets OR3O 
apart from the competition.”  

Smith+Nephew’s OR3O(TM) Dual Mobility System is available in Japan for both 
primary and revision applications and offers cross-compatibility with the 
R3(TM) Acetabular System.


References 
    1. Parikh A; Pawar V; Sprague J. Long-term Simulator Wear Performance of an 
       Advanced Bearing Technology for THA. Poster Presented at ORS. 2013; 
       Poster No:1028
    2. Darrith B, Courtney P.M., Della Valle C.J. Outcomes of dual 
       mobility components in total hip arthroplasty. Bone Joint J 
       2018;100-B:11–19.
    3. Australian Orthopaedic Association National Joint Replacement 
       Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2021: 2021 Annual 
       Report, Adelaide; AOA, 2021: 
       [Available at: https://aoanjrr.sahmri.com/annual-reports-2021 ]
    4. National Joint Registry for England, Wales and Northern Ireland, 18th 
       Annual Report [Available at: https://reports.njrcentre.org.uk/downloads ]
    5. American Joint Replacement Registry (AJRR), The Seventh Annual Report of 
       the AJRR on Hip and Knee Arthroplasty 2021, American Academy of 
       Orthopaedic Surgeons
    6. Italian Arthroplasty Register, Addendum to the Annual Report 2019, 
       English Version of Tables and Figures, October 2020
    7. Boyer, B., Philippot, R., Geringer, J. & Farizon, F. (2011). ‘Primary 
       total hip arthroplasty with dual mobility socketto prevent dislocation: 
       a 22-year follow-up of 240 hips’, International Orthopaedics (SICOT) 
       (2012) 36:511–518
    8. Spece, H., MacDonald, D. W., Mont, M. A., Lee, G.-C., and Kurtz, S. M., 
       “Fretting Corrosion and Polyethylene Damage Mechanisms in Modular Dual 
       Mobility Total Hip Arthroplasty,”Beyond the   Implant:   Retrieval 
       Analysis Methods for Implant Surveillance, ASTM STP1606
    9. Nam,D., Salih,R., Nahhas,C., Barrack,R. And Nunley,R, (2019). ‘Is a 
       modular dual mobility acetabulum a viable option for the young, active 
       total hip arthroplasty patient?’, Bone Joint J 2019;101-B:365–371
   10. Matsen Ko,L., Pollag,K., Yoo,J., & Sharkey,P (2015). ‘Serum Metal Ion 
       Levels Following Total Hip Arthroplasty With ModularDual Mobility 
       Components’, The Journal of Arthroplasty 31 (2016) 186–189
   11. Civinini,R., Cozzi Lepri,A., Carulli,C., Matassi,F., Villano,M., & 
       Innocenti,M. (2019). ‘Patients Following Revision Total Hip Arthroplasty 
       With ModularDual Mobility Components and Cobalt-Chromium Inner MetalHead 
       are at Risk of Increased Serum Metal Ion Levels’, The Journal of 
       Arthroplasty 35 (2020) S294eS298
   12. Romero,J., Wach,A., Silberberg,S., Chiu,Y., Westrich,G., Wright,T., & 
       Padgett,D. (2020) ‘2020 Otto Aufranc Award: Malseating of modular dual 
       mobility liners; Incidence and Implications’ ,Bone Joint J 2020;102-B(7 
       Supple B):20–26
   13. Lee,G., Kamath,A. & Maxwell Courtney,P. (2020). ‘Clinical Concerns With 
       Dual Mobility- Should I Avoid it When Possible?’, Article in Press, The 
       Journal of Arthroplasty xxx (2021) 1e4
   14. Gkiatas,I., Sharma,A., Greenberg,A., Duncan,S., Chalmers,B. & Sculco,P. 
       (2020). ‘Serum metal ion levels in modular dual mobility acetabular 
       components: A systematic review’, Journal of Orthopaedics 21 (2020) 432– 
       437
   15. Steven M. Kurtz et al. (2015) ‘Is There Material Loss at the Backside 
       Taper in Modular CoCr Acetabular Liners?’, Clinical Orthopaedics and 
       Related Research, 473:275–285
   16. Lombardo,D., Siljander,M., Gehrke,C., Moore,D., Karadsheh,M. & Baker,E. 
       (2018). ‘Fretting and Corrosion Damage of Retrieved Dual-Mobility 
       TotalHip Arthroplasty Systems’, The Journal of Arthroplasty 34 (2019) 
       1273e1278
   17. Kolz,J., Wyles,C., Van Citters,D., Chapman,R., Trousdale,R. & Berry,D. 
       (2020). ‘In Vivo Corrosion of Modular Dual-Mobility Implants:A Retrieval 
       Study’, The Journal of Arthroplasty 35 (2020) 3326e3329
   18. Sonn,K. & Meneghini,R. (2020). ‘Case report: Adverse Local Tissue 
       Reaction due to Acetabular Corrosion in Modular Dual-Mobility 
       Constructs’, Arthroplasty Today 6 (2020) 976e980
   19. Tarity,T., Koch,C., Burket,J., Wright,T. & Westrich,G. (2016). ‘Fretting 
       and Corrosion at the Backside of Modular Cobalt ChromiumAcetabular 
       Inserts: A Retrieval Analysis’, The Journal of Arthroplasty 32 (2017) 
       1033e1039
   20. D. C. Markel, T. Bou-Akl, M. D. Rossi, N. Pizzimenti, B. Wu, W. Ren 
       (2019). ‘Blood metal levels, leucocyte profiles, and cytokine profiles 
       in patients with a modular dual-mobility hip prosthesis: Early results 
       from a prospective cohort study’, Bone Joint J 2019;101-B:1035–1041

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, 
regeneration and replacement of soft and hard tissue. We exist to restore 
people’s bodies and their self-belief by using technology to take the limits 
off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver 
this mission every day, making a difference to patients’ lives through the 
excellence of our product portfolio, and the invention and application of new 
technologies across our three global franchises of Orthopaedics, Sports 
Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and 
generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent 
of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are 
used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless 
the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and 
follow us on Twitter ( http://www.twitter.com/smithnephewplc ), LinkedIn ( 
http://www.linkedin.com/company/smith-%26-nephew ), Instagram  ( 
https://www.instagram.com/smithnephewmeded/ ) or Facebook ( 
http://www.facebook.com/smithnephewplc ).

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove 
accurate. For example, statements regarding expected revenue growth and trading 
margins, market trends and our product pipeline are forward-looking statements. 
Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", 
"believe", "estimate", "expect", "target", "consider" and similar expressions 
are generally intended to identify forward-looking statements. Forward-looking 
statements involve known and unknown risks, uncertainties and other important 
factors that could cause actual results to differ materially from what is 
expressed or implied by the statements. For Smith+Nephew, these factors 
include: risks related to the impact of COVID-19, such as the depth and 
longevity of its impact, government actions and other restrictive measures 
taken in response, material delays and cancellations of elective procedures, 
reduced procedure capacity at medical facilities, restricted access for sales 
representatives to medical facilities, or our ability to execute business 
continuity plans as a result of COVID-19; economic and financial conditions in 
the markets we serve, especially those affecting health care providers, payers 
and customers (including, without limitation, as a result of COVID-19); price 
levels for established and innovative medical devices; developments in medical 
technology; regulatory approvals, reimbursement decisions or other government 
actions; product defects or recalls or other problems with quality management 
systems or failure to comply with related regulations; litigation relating to 
patent or other claims; legal compliance risks and related investigative, 
remedial or enforcement actions; disruption to our supply chain or operations 
or those of our suppliers (including, without limitation, as a result of 
COVID-19); competition for qualified personnel; strategic actions, including 
acquisitions and dispositions, our success in performing due diligence, valuing 
and integrating acquired businesses; disruption that may result from 
transactions or other changes we make in our business plans or organisation to 
adapt to market developments; and numerous other matters that affect us or our 
markets, including those of a political, economic, business, competitive or 
reputational nature. Please refer to the documents that Smith+Nephew has filed 
with the U.S. Securities and Exchange Commission under the U.S. Securities 
Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual 
report on Form 20-F, for a discussion of certain of these factors. Any 
forward-looking statement is based on information available to Smith+Nephew as 
of the date of the statement. All written or oral forward-looking statements 
attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does 
not undertake any obligation to update or revise any forward-looking statement 
to reflect any change in circumstances or in Smith+Nephew's expectations.

(TM) Trademark of Smith+Nephew. Certain marks registered US Patent and 
Trademark Office.

SOURCE  Smith & Nephew plc

Media Enquiries:  David Snyder, Smith+Nephew, +1 978-749-1440